Portage, Michigan–based Stryker received FDA 510(k) clearance for Incompass in June. It intends to begin the launch at the 2025 AOFAS Annual Meeting in Savannah, Georgia, this week.

Incompass — cleared for patients with end-stage ankle arthritis — introduces an innovative implant with an enhanced instrument platform. The orthopedic giant designed the implant for patients with ankle joints damaged by severe rheumatoid, post-traumatic or degenerative arthritis. The company says its new platform integrates the technologies of its Inbone and Infinity systems into a single, comprehensive system.

Stryker said the system offers intraoperative flexibility, enabling surgeons to adjust implant configurations in real-time. It features 3D-printed porous metal tibial and talar components engineered to promote bony ingrowth. By combining implant options and reducing instrumentation, the system helps reduce procedural complexity, enhance decision-making and lower sterilization demands, Stryker says.